Enhancing collaboration between academia and industry in kidney disease research

Abstract

Full text

In recent years, medical research and drug development have seen remarkable progress in various fields, but nephrology continues to lag behind. Kidney disease research faces numerous challenges, with drug approvals for nephrology averaging less than 1% of all new approvals in the past 5 years [1]. Addressing these gaps and improving outcomes for kidney disease patients require more effective collaboration between academia and the pharmaceutical industry, whose resources and expertise are essential to overcome the barriers slowing nephrology's advancement.

Kidney diseases are uniquely complex, marked by high heterogeneity across patient populations. Clinical manifestations, disease progression and responses to treatment vary widely, complicating the identification of effective therapeutic targets. In addition, the limited translatability of animal models, the slow progression of kidney diseases and the lack of reliable biomarkers compound the challenge, making it difficult to design and complete clinical trials within reasonable timelines [2]. Unlike fields such as oncology, where biomarkers have revolutionized clinical trials, nephrology still relies heavily on markers like albuminuria and proteinuria, which lack precision in predicting treatment outcomes and disease progression. The absence of more sophisticated biomarkers makes it harder to identify patients likely to benefit from new treatments, ultimately slowing trial efficiency and drug development.

To accelerate nephrology research and drug development, a well-defined framework is essential to facilitate collaboration between academia and industry. Such a framework must address significant barriers, including intellectual property (IP) rights, differences in institutional priorities, cultural discrepancies and the crucial role of patient advocacy groups. The financial risks associated with drug development in nephrology are considerable (see Table 1) due to the high failure rates and prolonged timelines. Therefore, industry often takes a cautious approach, investing selectively. Collaboration models that share financial burdens, streamline treatment target identification and testing, and accelerate timelines are needed to make nephrology research viable and effective.

Innovation in drug development often begins with foundational academic research, where breakthroughs sometimes arise serendipitously, as in the case of sodium-glucose cotransporter 2 inhibition and glucagon-like peptide-1 receptor agonism for chronic kidney disease (CKD) [3, 4]. Academic institutions are key to identifying novel targets and understanding disease mechanisms, but translating these discoveries into treatments requires the resources and expertise of the pharmaceutical industry. Successful partnerships hinge on clear frameworks that align shared goals, address potential conflicts of interest, and balance both public health and commercial priorities.

To achieve this, several practicable strategies can help to foster collaboration:

However, despite such initiatives, significant barriers remain that must be addressed to make collaborations effective:

Creating a sustainable research model also requires developing a workforce proficient in both academic and commercial research environments. Programmes offering dual roles or fellowships, like the MRC and AstraZeneca initiative, allow young researchers to gain hands-on experience across sectors, equipping them to advance drug development in complex fields like nephrology. Established clinical scientists could also benefit from industry secondments, exchanging knowledge and experience that ultimately benefit both academia and industry. However, making it possible to balance clinical duties with industry experience will be crucial in cultivating the next generation of clinician-scientists, whose cross-disciplinary expertise will be essential for tackling the unique challenges in kidney disease research.

Balancing collaboration between academia and the pharmaceutical industry is critical to advancing drug development in nephrology. Pharmaceutical companies face challenges beyond scientific discovery, such as technical, operational and financial hurdles. Long-term partnerships between academia and industry can yield substantial, enduring benefits. By committing to sustained collaboration and addressing the barriers discussed, academia and industry can ensure resources are used efficiently, advancing research aligned with both scientific and patient needs. This approach is vital in nephrology, where disease complexities demand a concerted, well-coordinated effort focused on patient benefit.

In ‘grasping the nettle’ and forging these essential partnerships, the future of kidney disease research holds great promise. As researchers harness the power of multi-omics and artificial intelligence applications, the classification of renal diseases may evolve, encouraging a shift away from what might be described as CKD treatments toward disease-specific drug targets. By identifying precise molecular and genetic markers, this approach could lead to targeted treatments that can address the subtleties of individual kidney diseases. Such advancement would be a major step forward in kidney research, aligning new drug development more closely with the diverse and complex realities of kidney disease.

With long-term, transparent collaborations, academia and industry can accelerate innovation, overcome current obstacles and ultimately transform kidney disease treatment—ensuring patients benefit from every advance made in nephrology research.